Alivus Life Sciences to host investor meet at Kotak Healthcare Forum
NiveshIQ
NSE: ALIVUS · Healthcare
Alivus Life Sciences Ltd.
₹1,386.80▼ ₹3.40 (-0.24%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ALIVUS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alivus Life Sciences Ltd.
Alivus Life Sciences Limited is a global API manufacturer with a diversified portfolio that includes cardiovascular, CNS, diabetes, oncology, and urology APIs such as amiodarone, ezetimibe, and sitagliptin. The company generates ₹2,590 crore in revenue, with net income of ₹603 crore, reflecting a strong profit margin driven by high‑value specialty APIs and contract manufacturing services. Recent developments include approval of a ₹5 dividend and FY26 results at the AGM, signalling shareholder value focus. Alivus maintains a competitive edge through its multi‑country manufacturing footprint and robust R&D pipeline, enabling it to meet diverse regulatory standards across key markets. The firm’s growth outlook is supported by expanding demand for specialty APIs, a growing contract manufacturi
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,185 Cr +6.70% | ₹2,340 Cr +7.10% | ₹2,552 Cr +9.10% |
| EBITDA Margin | 31.41% | 31.53% | 33.61% |
| Net Profit | ₹470.89 Cr +0.80% | ₹485.63 Cr +3.10% | ₹564.48 Cr +16.20% |
| EPS | ₹38.43 | ₹18.96 | ₹45.99 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Alivus Life Sciences (NSE:ALIVUS): What Is the Kotak Healthcare Forum 2026 Participation About?
Alivus Life Sciences passes ₹5 dividend, approves FY26 results at AGM
🔒
+ 3 more stories about Alivus Life Sciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹640 Cr, PAT ₹160 Cr, EPS ₹13.04, EBITDA margin 36.6%. Growth context: revenue QoQ -7.1%, PAT QoQ -1.6%. Street verdict: inline, revenue surprise -5.8%, PAT surprise +7.8%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline remain the key forward drivers ...
FY26 (last completed FY): revenue ₹2, 552 Cr, PAT ₹564 Cr, EBITDA margin 33.6%, EPS ₹45.99. Year-on-year: revenue YoY +9...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ALIVUS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ALIVUS alongside your other holdings
Unlock full ALIVUS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alivus Life Sciences Ltd.?
NiveshIQ detects active intelligence signals for Alivus Life Sciences Ltd. (ALIVUS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alivus Life Sciences Ltd.?
Alivus Life Sciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,378,329.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.